1. 1134. Lenzilumab Treatment in COVID-19 Pneumonia Reduces Circulating Cytokines and Markers of Systemic Inflammation. (15th December 2022) Authors: Chappell, Dale; Kilcoyne, Adrian; Cerasoli, Frank; Lukas, John; Durrant, Cameron; Temesgen, Zelalem; Polk, Christopher; Baker, Jason; Marconi, Vincent Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 23: LENZILUMAB IN HOSPITALIZED BLACK/AFRICAN-AMERICAN COVID-19 PATIENTS. (January 2022) Authors: Temesgen, Zelalem; Burger, Charles; Libertin, Claudia; Durrant, Cameron; Chappell, Dale; Ahmed, Omar; Kilcoyne, Adrian; Chappell, Gabrielle; Jordan, Edward; Badley, Andrew Journal: Critical care medicine Issue: Volume 50(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 23: LENZILUMAB IN HOSPITALIZED BLACK/AFRICAN-AMERICAN COVID-19 PATIENTS: LIVE-AIR PHASE 3 STUDY RESULTS. (16th December 2021) Authors: Temesgen, Zelalem; Burger, Charles; Libertin, Claudia; Durrant, Cameron; Chappell, Dale; Ahmed, Omar; Kilcoyne, Adrian; Chappell, Gabrielle; Jordan, Edward; Badley, Andrew Journal: Critical care medicine Issue: Volume 50(2022)Supplement 1 Page Start: 12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 40. Lenzilumab Efficacy and Safety in Newly Hospitalized COVID-19 Subjects: Results From a Phase 3 Randomized Double-Blind Placebo-Controlled Trial. (4th December 2021) Authors: Temesgem, Zelalem; Burger, Charles; Baker, Jason; Polk, Christopher; Libertin, Claudia R; Kelley, Colleen F; Marconi, Vincent; Orenstein, Robert; Catterson, Victoria; Aronstein, William; Durrant, Cameron; Chappell, Dale; Ahmed, Omar; Chappell, Gabrielle; Badley, Andrew Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA. (11th November 2019) Authors: Gan, Hui; Cher, Lawrence; Inglis, Po; Lwin, Zarnie; Lau, Eddie; Ackermann, Uwe; Coombs, Nicole; Remen, Kirsten; Guo, Nancy; Ting Lee, Sze; Gong, Sylvia; Palmer, Jodie; Pathmaraj, Kunthi; O'Keefe, Graeme; Scott, Fiona; Day, Bryan; Boyd, Andrew; Thomas, Paul; Durrant, Cameron; Scott, Andrew Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Graded Microstructure of Additive Manufactured Ti-6Al-4V via Electron Beam Melting. (August 2019) Authors: Chen, Hansheng; Cooper, Christopher; Durrant, Cameron; Li, Yingluo; Primig, Sophie; Liao, Xiaozhou; Babu, Sudarsanam Suresh; Ringer, Simon P. Journal: Microscopy and microanalysis Issue: Volume 25:(2022)Supplement 2 Page Start: 498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Issue 3 (March 2022) Authors: Temesgen, Zelalem; Burger, Charles D; Baker, Jason; Polk, Christopher; Libertin, Claudia R; Kelley, Colleen F; Marconi, Vincent C; Orenstein, Robert; Catterson, Victoria M; Aronstein, William S; Durrant, Cameron; Chappell, Dale; Ahmed, Omar; Chappell, Gabrielle; Badley, Andrew D; Lewis, Meghan; S... Journal: Lancet Issue: Volume 10:Issue 3(2022) Page Start: 237 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗